Skip to main
ANIP

ANI Pharma (ANIP) Stock Forecast & Price Target

ANI Pharma (ANIP) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

ANI Pharmaceuticals Inc. has demonstrated a commitment to enhancing its revenue potential through the expansion of its Cortrophin sales force, which has been identified as a significant driver of product success. This strategic move provides the company with increased financial flexibility to invest further in Cortrophin, which is expected to lead to positive revenue estimates and multiple expansions. Furthermore, the effectiveness of their data-driven approach has strengthened ANI's ability to address payer-related inquiries, thereby improving the approval process for prescriptions, which is likely to contribute to overall revenue growth.

Bears say

ANI Pharmaceuticals Inc faces significant financial challenges that contribute to a negative outlook on its stock. The company carries a substantial debt load exceeding $600 million, which raises concerns about its financial stability, especially considering the risks associated with pricing, reimbursement, and competition in the generic pharmaceuticals market. Additionally, past reputational issues within the ACTH category, coupled with manufacturing and commercial execution risks, further exacerbate the uncertainties surrounding the company's operational effectiveness and overall performance.

ANI Pharma (ANIP) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ANI Pharma (ANIP) Forecast

Analysts have given ANI Pharma (ANIP) a Buy based on their latest research and market trends.

According to 6 analysts, ANI Pharma (ANIP) has a Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $103.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $103.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ANI Pharma (ANIP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.